Trial Profile
Golimumab study for development of tight control and biologics-free condition.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms Go-sunrising
- 10 Jul 2020 Status changed from recruiting to discontinued.
- 02 Dec 2014 New trial record